Iovance Biotherapeutics (IOVA) News Today

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 6%

Seven Eight Capital LP acquired a new stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 174,402 shares o

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) - Equities researchers at Zacks Research lowered their Q1 2025 earnings per share (EPS) estimates for shares of Iovance Biotherapeutics in a research note issued on Wednesday, July 17th. Zacks Research analyst S. Ganoria now anticipates th

BNP Paribas Financial Markets cut its position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 73.6% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 145,924 shares of th

StockNews.com upgraded Iovance Biotherapeutics to a "sell" rating in a report on Friday.

Iovance Biotherapeutics (NASDAQ:IOVA) Trading 9.4% Higher

Vanguard Group Inc. increased its stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 3.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,812,820 shares of the bi

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 2.5%

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) was the target of a large increase in short interest during the month of June. As of June 15th, there was short interest totalling 54,630,000 shares, an increase of 9.3% from the May 31st total of 49,960,000 shares. Based on an average daily volume of 5,860,000 shares, the short-interest ratio is currently 9.3 days. Approximately 24.4% of the shares of the company are short sold.

Iovance Biotherapeutics (NASDAQ:IOVA) Trading 1.7% Higher

Hennion & Walsh Asset Management Inc. raised its holdings in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 42.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 407,429 shares of the bi

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 1.6%

HC Wainwright restated a "buy" rating and issued a $32.00 target price on shares of Iovance Biotherapeutics in a research note on Friday.

Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 0.6%

Iovance Biotherapeutics (NASDAQ:IOVA) Trading Down 2.2%

Iovance Biotherapeutics (NASDAQ:IOVA) Trading Up 1.9%

JMP Securities decreased their price target on Iovance Biotherapeutics from $25.00 to $23.00 and set a "market outperform" rating on the stock in a report on Thursday.

Iovance Biotherapeutics (NASDAQ:IOVA) Trading Down 0.7%

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Down 1.5%

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) has earned an average rating of "Buy" from the ten analysts that are presently covering the stock, Marketbeat Ratings reports. Ten analysts have rated the stock with a buy rating. The average 12-month price target among brokers that hav

Opaleye Management Inc. raised its position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 47.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 897,000 shares of the biotech

Boxer Capital LLC reduced its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 62.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,400,000 shares of the biotechnology compa

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Gap Up to $8.62

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 5.5%

Invenomic Capital Management LP acquired a new position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 1,053,251 shares of the biotechnology compan

Sectoral Asset Management Inc. trimmed its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 79.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 198,800 shares of the biote

UBS Group AG boosted its holdings in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 255.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 857,308 shares of the biotechnology company's stock after

Rafferty Asset Management LLC cut its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 16.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,247,515 shares of the biotec

Rhenman & Partners Asset Management AB grew its position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 17.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,116,818 shares of the bi

Dimensional Fund Advisors LP trimmed its position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 11.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,516,987 shares of the biotechnology

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) - Research analysts at Zacks Research upped their Q2 2024 earnings per share (EPS) estimates for shares of Iovance Biotherapeutics in a report issued on Wednesday, May 29th. Zacks Research analyst S. Ganoria now expects that the biotechnol

Corient Private Wealth LLC raised its stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 206.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 367,000 shares o

Artisan Partners Limited Partnership lessened its holdings in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 4.1% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,827,670 shares of the biotechnology company's s